Skip to main content

Advertisement

Table 3 Dosimetric endpoint comparison between Cyberknife and VMAT plans

From: Benchmarking techniques for stereotactic body radiotherapy for early-stage glottic laryngeal cancer: LINAC-based non-coplanar VMAT vs. Cyberknife planning

Average (S.D.) PTV Dmax (Gy) Left/Right Carotid Artery Dmax (Gy) Left/Right Carotid Artery Dmean (Gy) Thyroid Gland Dmean (Gy) Spinal Cord Dmax (Gy) Skin Dmax (Gy)
 Cyberknife 48.3 (1.2) 13.9 (4.4) 6.6 (2.4) 4.3 (2.2) 5.8 (2.2) 41.4 (2.9)
 VMAT-AXB 46.5* (0.8) 12.7 (3.1) 7.1 (2.4) 2.4* (2.1) 8.2 (2.2) 41.3 (3.5)
 VMAT-AAA 46.6* (0.9) 12.9 (3.1) 7.1 (2.4) 2.7* (2.5) 7.9 (2.2) 40.1 (5.0)
Average (S.D.) Contralateral Arytenoid Dmax (Gy) R50 R20 Conformity index MU  
 Cyberknife 17.9 (4.8) 5.0 (0.6) 17.4 (3.0) 1.13 (0.07) 7333 (1934)
 VMAT-AXB 17.2 (2.9) 5.9* (0.8) 20.2 (3.2) 1.20 (0.10) 2095* (259)
 VMAT-AAA 15.2* (4.0) 5.7* (0.7) 19.2 (3.1) 1.19 (0.05) 2311* (343)
  1. The metric values were presented as the average of all ten patients studied, with numbers in brackets showing the standard deviations. The “*” mark was added when the difference between the Cyberknife and the VMAT-AXB or between the Cyberknife and the VMAT-AAA was statistically significant (p < 0.025)